Literature DB >> 15142549

[11C]Choline as a PET biomarker for assessment of prostate cancer tumor models.

Qi-Huang Zheng1, Thomas A Gardner, Sudhanshu Raikwar, Chinghai Kao, K Lee Stone, Tanya D Martinez, Bruce H Mock, Xiangshu Fei, Ji-Quan Wang, Gary D Hutchins.   

Abstract

[(11)C]Choline has been evaluated as a positron emission tomography (PET) biomarker for assessment of established human prostate cancer tumor models. [(11)C]Choline was prepared by the reaction of [(11)C]methyl triflate with 2-dimethylaminoethanol (DMAE) and isolated and purified by solid-phase extraction (SPE) method in 60-85% yield based on [(11)C]CO(2), 15-20 min overall synthesis time from end of bombardment (EOB), 95-99% radiochemical purity and specific activity >0.8 Ci/micromol at end of synthesis (EOS). The biodistribution of [(11)C]choline was determined at 30 min post iv injection in prostate cancer tumor models C4-2, PC-3, CWR22rv, and LNCaP tumor-bearing athymic mice. The results showed the accumulation of [(11)C]choline in these tumors was 1.0% dose/g in C4-2 mouse, 0.4% dose/g in PC-3 mice, 3.2% dose/g in CWR22rv mice, and 1.4% dose/g in LNCaP mice; the ratios of tumor/muscle (T/M) and tumor/blood (T/B) were 2.3 (T/M, C4-2), 1.4 (T/M, PC-3), 2.5 (T/M, CWR22rv), 1.2 (T/M, LNCaP) and 2.6 (T/B, C4-2), 2.6 (T/B, PC-3), 7.8 (T/B, CWR22rv), 3.2 (T/B, LNCaP), respectively. The micro-PET imaging of [(11)C]choline in prostate cancer tumor models was acquired from a C4-2, PC-3, CWR22rv, or LNCaP implanted mouse at 30 min post iv injection of 1 mCi of the tracer using a dedicated high resolution (<3 mm full-width at half-maximum) small FOV (field-of-view) PET imaging system, IndyPET-II scanner, developed in our laboratory, which showed the accumulation of [(11)C]choline in C4-2, PC-3, CWR22rv, or LNCaP tumor implanted in a nude athymic mouse. The initial dynamic micro-PET imaging data indicated the average T/M ratios were approximately 3.0 (C4-2), 2.1 (PC-3), 3.5 (CWR22rv), and 3.3 (LNCaP), respectively, which showed the tumor accumulation of [(11)C]choline in all four tumor models is high. These results suggest that there are significant differences in [(11)C]choline accumulation between these different tumor types, and these differences might offer some useful measure of tumor biological process.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15142549     DOI: 10.1016/j.bmc.2004.03.051

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  20 in total

1.  Effects of flutamide on [methyl-(3)h]-choline uptake in human prostate cancer-3 cells: a pilot study.

Authors:  Fatma Al-Saeedi
Journal:  Curr Ther Res Clin Exp       Date:  2007-07

2.  Comparison of [(11)C]Choline ([(11)C]CHO) and [(18)F]Bombesin (BAY 86-4367) as Imaging Probes for Prostate Cancer in a PC-3 Prostate Cancer Xenograft Model.

Authors:  Sarah Marie Schwarzenböck; Philipp Schmeja; Jens Kurth; Michael Souvatzoglou; Roman Nawroth; Uwe Treiber; Guenther Kundt; Sandra Berndt; Keith Graham; Reingard Senekowitsch-Schmidtke; Markus Schwaiger; Sibylle I Ziegler; Ludger Dinkelborg; Hans-Jürgen Wester; Bernd Joachim Krause
Journal:  Mol Imaging Biol       Date:  2016-06       Impact factor: 3.488

3.  In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer.

Authors:  Anthonius J Breeuwsma; Jan Pruim; Maud M Jongen; Albert J Suurmeijer; Wim Vaalburg; Rien J Nijman; Igle J de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03-12       Impact factor: 9.236

4.  Imaging in the diagnosis and management of prostate cancer.

Authors:  Samir S Taneja
Journal:  Rev Urol       Date:  2004

5.  Characterization of osteolytic, osteoblastic, and mixed lesions in a prostate cancer mouse model using 18F-FDG and 18F-fluoride PET/CT.

Authors:  Wellington K Hsu; Mandeep S Virk; Brian T Feeley; David B Stout; Arion F Chatziioannou; Jay R Lieberman
Journal:  J Nucl Med       Date:  2008-02-20       Impact factor: 10.057

6.  Preclinical evaluation of the novel monoclonal antibody H6-11 for prostate cancer imaging.

Authors:  Hongjun Jin; Mai Xu; Prashanth K Padakanti; Yongjian Liu; Suzanne Lapi; Zhude Tu
Journal:  Mol Pharm       Date:  2013-09-03       Impact factor: 4.939

Review 7.  Molecular imaging of prostate cancer: a concise synopsis.

Authors:  Hossein Jadvar
Journal:  Mol Imaging       Date:  2009 Mar-Apr       Impact factor: 4.488

8.  Comparison of [¹¹C]choline ([¹¹C]CHO) and S(+)-β-methyl-[¹¹C]choline ([¹¹C]SMC) as imaging probes for prostate cancer in a PC-3 prostate cancer xenograft model.

Authors:  Sarah Marie Schwarzenböck; Jana Gertz; Michael Souvatzoglou; Jens Kurth; David Sachs; Roman Nawroth; Uwe Treiber; Tibor Schuster; Reingard Senekowitsch-Schmidtke; Markus Schwaiger; Sibylle Ilse Ziegler; Gjermund Henriksen; Hans-Jürgen Wester; Bernd Joachim Krause
Journal:  Mol Imaging Biol       Date:  2015-04       Impact factor: 3.488

9.  Choline autoradiography of human prostate cancer xenograft: effect of castration.

Authors:  Hossein Jadvar; Alparslan Gurbuz; Xiankui Li; Antranik Shahinian; Peter S Conti
Journal:  Mol Imaging       Date:  2008 May-Jun       Impact factor: 4.488

10.  Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study.

Authors:  Mohsen Beheshti; Reza Vali; Peter Waldenberger; Friedrich Fitz; Michael Nader; Wolfgang Loidl; Gabriele Broinger; Franz Stoiber; Ignac Foglman; Werner Langsteger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-09       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.